Yahoo
OTC Markets OTCQX - Delayed Quote USD

Sandoz Group AG (SDZXF)

100.50 0.00 (0.00%)
At close: October 30 at 5:00:00 PM EDT
Chart Range Bar
Loading chart for SDZXF
  • Previous Close 100.50
  • Open 100.50
  • Bid 98.05 x 30000
  • Ask 102.05 x 10000
  • Day's Range 100.50 - 100.50
  • 52 Week Range 66.29 - 100.50
  • Volume 200
  • Avg. Volume 73
  • Market Cap (intraday) 43.486B
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) 68.37
  • EPS (TTM) 1.47
  • Earnings Date Aug 5, 2026
  • Forward Dividend & Yield 1.02 (1.02%)
  • Ex-Dividend Date Apr 13, 2026
  • 1y Target Est --

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.

www.sandoz.com

20,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

SDZXF
42.41%
MSCI WORLD (^990100-USD-STRD)
9.06%

1-Year Return

SDZXF
53.36%
MSCI WORLD (^990100-USD-STRD)
9.89%

3-Year Return

SDZXF
276.95%
MSCI WORLD (^990100-USD-STRD)
0.00%

5-Year Return

SDZXF
261.25%
MSCI WORLD (^990100-USD-STRD)
53.16%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 3B
Earnings --
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q2

FY26

0
1B
2B
3B
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.53%

  • Return on Assets (ttm)

    3.05%

  • Return on Equity (ttm)

    7.25%

  • Revenue (ttm)

    11.68B

  • Net Income Avi to Common (ttm)

    646M

  • Diluted EPS (ttm)

    1.47

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.27B

  • Total Debt/Equity (mrq)

    68.92%

  • Levered Free Cash Flow (ttm)

    1.37B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: